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To determine whether the GARFIELD-AF integrated risk tool predicts mortality, non-
haemorrhagic stroke/systemic embolism (SE), and major bleeding for up to two years after new 
onset AF and to assess how this risk tool performs compared with CHA2DS2-VASc and HAS-
BLED.  
Methods and results 
Potential predictors of events included demographic and clinical characteristics, choice of 
treatment, and lifestyle factors. A Cox proportional hazards model was identified for each 
outcome by least absolute shrinkage and selection operator (LASSO) methods. Indices were 
evaluated in comparison with CHA2DS2-VASc and HAS-BLED risk predictors. Models were 
validated internally and externally in ORBIT-AF and Danish nationwide registries.   Among 
the 52,080 patients enrolled in GARFIELD-AF, 52,032 had follow-up data. The GARFIELD-
AF risk tool outperformed CHA2DS2-VASc for all-cause mortality in all cohorts.  The 
GARFIELD-AF risk score was superior to CHA2DS2-VASc for non-haemorrhagic stroke, and 
it outperformed HAS-BLED for major bleeding in internal validation and in Danish AF cohort. 
In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the 
GARFIELD-AF risk score offered strong discriminatory value for all the endpoints when 
compared to CHA2DS2-VASc and HAS-BLED. The GARFIELD-AF tool also included the 
effect of OAC therapy, thus allowing clinicians to compare the expected outcome of different 
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The GARFIELD-AF risk tool outperformed CHA2DS2-VASc at predicting death and non-
haemorrhagic stroke, and it outperformed HAS-BLED for major bleeding in overall as well as 
in very low to low risk group patients with AF.  
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Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with a nearly 
five-fold increased risk of stroke and two-fold increased risk of death (1, 2). The 2020 ESC 
guidelines for the diagnosis and management of AF suggest using the CHA2DS2-VASc risk 
score to identify patients at low risk (CHA2DS2-VASc score = 0 in men, or 1 in women) for 
whom antithrombotic therapy should not be prescribed. Oral anticoagulation (OACs) should 
be prescribed for stroke prevention in patients with CHA2DS2-VASc score ≥2 in men, or ≥3 in 
women and should considered in patients with a CHA2DS2-VASc score of 1 in men, or 2 in 
women. HAS-BLED is recommended to identify patients at high risk of bleeding. Non-VKA 
oral anticoagulants (NOACs) are recommended in preference to oral vitamin K antagonists 
(VKAs) except in patients with rheumatic mitral valve disease and/or an artificial heart valve 
(3). 
We previously developed a Global Anticoagulant Registry in the FIELD–Atrial Fibrillation 
(GARFIELD-AF) risk model to predict all-cause mortality, stroke, and bleeding risks in 
patients with newly diagnosed AF. The early evaluation indicated that this was superior to 
existing risk scores for stroke (CHA2DS2-VASc) and bleeding (HAS-BLED) (4). The 
nationwide Danish AF cohort provides external validation and indicates that the GARFIELD-
AF model is superior to CHA2DS2-VASc in predicting stroke/SE and is comparable with HAS-
BLED for predicting major bleeding (5). Integrated clinical scores like GARFIELD-AF and 
other scores which incorporate biomarker measurement (6) demonstrate statistically significant 
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In this report, we aimed (1) to derive and validate a new risk model for predicting mortality, 
non-haemorrhagic stroke/SE and major bleeding up to two years after enrolment based on 
treatment selection. (2) To include the feature of treatment selection in GARFIELD-AF risk 
calculator to assist clinicians in applying guideline adherence to anticoagulation decisions for 
patients with AF.  
MATERIALS AND METHODS 
Registry population  
The analysis was conducted in 52,080 patients enrolled in GARFIELD-AF between March 
2010 and July 2016. The data were extracted from the study database on 19 November 2018. 
To minimize recruitment bias in GARFIELD-AF, investigator sites were selected randomly 
from representative care settings in each participating country (apart from 18 sites, out of 
>1000) and consecutive patients were enrolled, regardless of whether or not they received 
antithrombotic treatment. Eligible patients comprised adults (aged ≥18 years) who had been 
newly diagnosed with AF (not related to mechanical valves or severe valve disease), within the 
previous 6 weeks and had at least one unspecified risk factor for stroke as judged by the 
investigator.  
Study procedures and outcome measures 
The methods employed in GARFIELD-AF have been published (7, 8). In brief, baseline 
characteristics included: patient characteristics, medical history, care settings, type of AF, date 
and method of diagnosis, symptoms of AF, type of anticoagulant treatment (VKAs, factor Xa 
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Data on components of the CHA2DS2-VASc (9) and HAS-BLED (10) risk stratification 
schemes were also collected to assess the risks of non-haemorrhagic stroke and major bleeding. 
Collection of follow-up data occurred at 4-monthly intervals based on telephone interviews 
and hospital records up to 24 months. The incidence of ischaemic stroke, transient ischaemic 
attack (TIA), systemic embolism (SE), acute coronary syndrome (ACS), hospitalisation, death 
(cardiovascular and non-cardiovascular), Congestive heart failure (CHF) (occurrence or 
worsening), and bleeding (severity and location) was documented. An audit and quality control 
programme was applied (11), and data were examined for completeness and accuracy by the 
coordinating centre (TRI, London, UK). By design, 20% of all electronic case report forms 
(eCRFs) in the GARFIELD-AF registry were monitored against source documentation at sites 
over the recruitment period and follow-up. Loss to follow-up was found to be 4.2% of all 
prospectively enrolled patients. Any events that occurred after two years follow-up were 
censored at two years. Patients with unavailable follow-up information were excluded from all 
the analyses. 
Risk tool Design 
The new risk stratification tool was derived from prospective data from the GARFIELD-AF 
registry.  Models were trained on indicators for three events (all-cause mortality, non-
haemorrhagic stroke/systemic embolism, and any major bleed) that occurred within 2 years of 
enrolment. As with the previous GARFIELD-AF risk models, the derivation of the 
GARFIELD-AF risk models followed the TRIPOD process for the development of predictive 
models (4, 12). 
Comparisons of the performance of the new GARFIELD-AF risk models were made with (a) 
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BLED score for major bleeding. The performance of the new risk tool was tested in the whole 
GARFIELD-AF population as well as in patients treated and untreated with OACs for stroke 
prevention at baseline. 
We also tested our hypothesis that the performance of the GARFIELD-AF risk model would 
be superior to the CHA2DS2-VASc score in discriminating patients with a low stroke risk. We 
considered a CHA2DS2-VASc score of 0 or 1 (men) and 1 or 2 (women) who may not benefit 
from anticoagulation (as defined by the ESC Guidelines) as representative of “very low to low” 
risk. As a sensitivity analysis, we also evaluated those with a CHA2DS2-VASc score of 0-2 
(men) and 1-3 (women). 
The validity of the GARFIELD-AF risk models was tested externally in patients with AF from 
an independent US-based registry, the ORBIT-AF registry as well as the Danish nationwide 
registries (5, 13-16).  
Definitions  
Non-haemorrhagic stroke/SE was defined as the combined end points of: ischaemic stroke, 
unknown-type stroke, systemic embolism and TIA. Major bleed was classified by investigators 
according to the International Society on Thrombosis and Haemostasis (ISTH) definition (17). 
Major bleeds, including intracranial bleeds, were defined as a combined end point of 
haemorrhagic stroke and any major bleed. Minor/non-major clinically relevant (NMCR) bleeds 
that required transfusion or that occurred in a critical site were reclassified as major bleeds. 
 
Vascular disease included patients with peripheral artery disease or coronary artery disease 
(CAD). Hypertension was defined as a documented history of hypertension. Chronic kidney 
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Kidney Disease Outcomes Quality Initiative (NKF KDOQI) guidelines into two groups(18) 
moderate-to-severe, or mild or none. Congestive heart failure (CHF) was defined as 
current/prior history of congestive heart failure or left ventricular ejection fraction of <40%. 
Standard clinical definitions of stroke and TIA were used (19). ACS included unstable angina, 
STEMI, and non-STEMI.  
The CHA2DS2-VASc score was the sum of points after addition of one point each for CHF, 
hypertension, diabetes, vascular disease, age 65-74 years, and female gender, and two points 
each for age ≥75 years and previous ischaemic stroke and systemic embolism (9). The HAS-
BLED score was the sum of points after addition of one point each for uncontrolled 
hypertension (systolic blood pressure >160mmHg), moderate to severe CKD, cirrhosis, stroke 
history, bleeding history, elderly [>65] and heavy alcohol use (10) (fluctuations in international 
normalised ratios were not included in this study). 
 
Ethics statement 
Independent ethics committee and hospital-based institutional review board approvals were 
obtained, as necessary, for the registry protocol. Additional approvals were obtained from 
individual study sites. The registry is being conducted in accordance with the principles of the 
Declaration of Helsinki, local regulatory requirements, and the International Conference on 
Harmonisation Good Pharmacoepidemiological and Clinical Practice Guidelines. Written 
informed consent was obtained from all study participants. Confidentiality and anonymity of 
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Predictors of mortality, non-haemorrhagic stroke/SE, and major bleeding were identified using 
the least absolute shrinkage and selection operator (LASSO) regression. The predictors were 
selected from the list of potential predictors (Supplement List 1).  
 
A Cox model was fitted with the selected parameters. Thirty-fold cross-validation was applied 
during the modelling process. Both a Kolmogorov-type supremum statistical test and a 
graphical examination of the Schoenfeld residuals were used to assess the Cox model 
proportional hazards assumption. All continuous covariates were tested for linearity and 
appropriate transformations were applied as needed. One imputed dataset was used for the 
model generation. The final model was established with multiple imputation. Combined hazard 
ratio estimates with 95% CI from five imputations were presented. 
 
The equations using the base hazard and coefficients provide predicted probabilities for each 
outcome.  These same equations are used in an online risk tool which provides an easy method 
for inputting the patient values. 
 
Follow-up was censored at 2 years for those patients who were followed for a longer period.  
Comparison of the GARFIELD-AF risk model with existing scores (CHA2DS2-VASc, HAS-
BLED) was performed displaying the c-index with 95% CI for a measure of discrimination. 
Calibration curves were used to show how well the predicted values were calibrated to the 
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External validation  
We evaluated the performance of the GARFIELD-AF risk model in two external  populations:  
the ORBIT-AF registry (ORBIT-AF I and ORBIT-AF II) (13, 20) and the Danish nationwide 
registries including patients  with AF (Danish AF cohort) (5).  
ORBIT- AF Registry  
Each score was recreated according to the definitions given in the original GARFIELD-AF 
study, using baseline values from the first study visit in each registry. From the list of variables 
in the simplified model, only history of bleeding and of carotid occlusive disease were 
unavailable in ORBIT-AF. In GARFIELD-AF, history of any bleeding was considered 
(independent of severity or site). In ORBIT-AF, history of gastrointestinal bleeding (GI) was 
substituted for history of bleeding.  For the purpose of this validation, we considered that none 
of ORBIT-AF patients had carotid occlusive disease. 
Danish AF Cohort 
From the Danish Nationwide Patient Registry, patients aged ≥18 years with a primary or 
secondary diagnosis of AF or atrial flutter (International Classification of Diseases, Tenth 
Revision [ICD‐ 10]: I48), hospitalisation or outpatient visit, were included from January 1, 
2010 until August 1st, 2015 with follow-up to August 1st 2017. Patients with rheumatic 
valvular heart disease or valve interventions were excluded. To allow patients time to fill their 
prescriptions after discharge, a 10-day wash-out period was used. International Classification 
of Diseases, Tenth Revision (ICD-10) codes and Anatomical Therapeutic Chemical (ATC) 
codes were used as described in the previous publication (5). Additional codes were used for 
Carotid occlusion (DI625), diabetes (ICD-10, E10, E11, ATC-codes: A101A, A10B), and 
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like blood pressure, BMI, pulse, and smoking, the mean values from the GARFIELD-AF 
patients enrolled from Denmark, Sweden, Norway and Finland were used. The information on 
ethnicity was not available.  Thus, for the purpose of the validation, all patients with a status 




Of 52,080 patients enrolled, 52,032 (99.9%) had available follow-up data. Table 1 provides the 
baseline characteristics for the patients and for the outcomes occurred within 2 years of follow-
up. At baseline, the median (IQR) age was 71.0 (63.0 to 78.0) years, and 44.2% of patients 
were females. Overall, 66.8% of patients were prescribed AC therapy (39.3% VKAs and 27.5% 
NOACs, with or without APs), 21% received AP monotherapy, and 12.2% received no AC or 
AP therapy.  
Clinical Outcomes 
At 2 years, 3702 patients had died (event rate, 3.82 [95% CI, 3.70–3.95] per 100 patient-years) 
where as non-haemorrhagic stroke/SE occurred in 957 patients (rate, 1.00 [95% CI, 0.94–1.06] 
per 100 patient-years) and major bleed/haemorrhagic stroke in 935 patients (rate, 0.97 [95% 
CI, 0.91–1.04] per 100 patient-years). The cumulative incidence curves of the three outcomes 
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Predictors of all-cause mortality, non-haemorrhagic stroke/SE and major bleeding 
The following baseline variables were found to be significantly associated with all-cause 
mortality: age, sex, ethnicity, weight, diastolic blood pressure, pulse, CHF, CKD, vascular 
disease, diabetes, dementia, history of bleeding, prior stroke, treatment and smoking (Table 
2a). The variables associated with non-haemorrhagic stroke/SE were: age, diastolic blood 
pressure, prior stroke, CKD, CHF, dementia, diabetes, vascular disease, history of bleeding, 
treatment and smoking (Table 2b).  A higher risk of major bleeding was associated with older 
age, resting heart rate, CKD, diabetes, vascular disease, carotid occlusive disease, NOAC, 
VKA and AP treatments (Table 2b).  
Patients who received NOAC and VKA therapies demonstrated a reduction of all-cause 
mortality and non-haemorrhagic stroke/SE and increased risk of major bleeding when 
compared with those that received no oral anticoagulant (NOAC: HR 0.66 (0.61-0.72), 0.56 
(0.48-0.67), and 1.27 (1.05-1.55); VKA: HR 0.83 (0.77-0.90), 0.70 (0.61-0.81) and 1.84 (1.55-
2.18) respectively). NOAC use was associated with lower risk of all-cause mortality, non-
haemorrhagic stroke/SE, and major bleeding when compared with VKA. 
Performance of GARFIELD-AF risk models, CHA2DS2-VASc or HAS-BLED in 
GARFIELD-AF patients 
The GARFIELD-AF risk model for all-cause mortality, non-haemorrhagic stroke/SE and 
major bleeding is presented in figure 1. The GARFIELD-AF risk model for the all-cause 
mortality performed well in the overall population, AC treated, AC untreated, and in the lower 
risk groups; (C-index: 0.75, 0.74, 0.77 and 0.71, respectively). The GARFIELD-AF risk model 
for non-haemorrhagic stroke/SE and major bleeding also performed well in the overall 
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stroke/SE and bleeding model had an overall C-index of 0.68 (95% CI 0.67-0.70) and 0.68 
(95% CI 0.66 to 0.70), respectively. A good calibration between predicted and observed all-
cause mortality rates and an adequate calibration for non-haemorrhagic stroke/SE and major 
bleeding rates were observed. (Figure 2). 
Comparison of the GARFIELD-AF, CHA2DS2-VASc or HAS-BLED risk scores 
The performance of the GARFIELD-AF, CHA2DS2-VASc (or HAS-BLED for bleeding) risk 
models is shown in figure 1. The analyses demonstrate that the discriminatory value of the 
GARFIELD-AF integrated risk model was superior to CHA2DS2-VASc for all-cause mortality 
and non-haemorrhagic stroke/SE or HAS-BLED for major bleeding in the overall population, 
treated and untreated, as well as in the very low to low risk patients (CHA2DS2-VASc 0 or 1 
for men and 1-2 for women/ HAS-BLED 0 or 1 for major bleeding / haemorrhagic stroke). 
The GARFIELD-AF models provided additional information for all endpoints in the lower risk 
groups when compared with CHA2DS2-VASc or HAS-BLED. Whereas, CHA2DS2-VASc 
offered poor discrimination for mortality (C-index 0.52 (0.49-0.56)) and non-haemorrhagic 
stroke/SE (C-index 0.52 (0.46-0.58)) and HAS-BLED for bleeding (C-index 0.56 (0.55-0.58)) 
in low-risk group (Figure 1). 
Internal validations 
Internal validation of the GARFIELD-AF risk models at 2 year of follow-up is presented in 
supplementary table S1. The three models have a low change in the C-statistic after adjusting 
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Distribution of CHA2DS2-VASc scores by GARFIELD-AF stroke score deciles 
The distribution of CHA2DS2-VASc scores: (0 (men)/1 (women) for whom OAC should not 
be prescribed, 1 (men)/2 (women) for whom OAC should be considered and >1 (men)/>2 
(women) for whom OAC should be prescribed for stroke prevention as per ESC guidelines) by 
GARFIELD-AF stroke score deciles are shown in figure 3. A high proportion of patients in the 
lowest two deciles of risk according to the GARFIELD-AF stroke scores would likely be 
treated with OACs based on the CHA2DS2-VASc scores. Up to 24% of very low risk patients 
(GARFIELD-AF 1st decile) were CHA2DS2-VASc ≥2 (excluding gender). As stroke risk 
increased according to GARFIELD-AF, the CHA2DS2-VASc score also increased. All high 
risk patients according to the GARFIELD-AF stroke score (10th decile) were CHA2DS2-VASc 
≥2 (excluding gender). 
 The observed stroke incidence estimates by CHA2DS2-VASc score and GARFIELD-AF 
stroke risk category are presented in supplementary table S2. The GARFIELD-AF score shows 
additional increases in risk within each of the four groupings of the CHA2DS2-VASc score.  
For example, for patients with a CHA2DS2-VASc score of 2-3, the actual 2-year rate of non-
haemorrhagic stroke/SE increases from 0.80 to 2.86 across the quartiles of GARFIELD-AF 
risk scores.  This increase in risk across GARFIELD-AF risk quartiles is seen within each of 
the four CHA2DS2-VASc score categories.  Correspondingly, this trend for increasing event 
rates is also true for increasing CHA2DS2-VASc scores within the two high quartiles of 
GARFIELD-AF risk.  However, there seems to be little differentiation of risk, using CHA2DS2-
VASc, when moving from 0-1 to 2-3 for the lowest quartile of risk or for 0-1 to 2-3 to 4-5 for 
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External validation of GARFIELD-AF risk models in the ORBIT-AF and Danish AF 
cohort 
The external validation of the GARFIELD-AF risk model was done in ORBIT-AF, an 
independent population registry from the US registry and Danish AF cohort consisting of 
patients with AF derived from the Danish nationwide registries. The calibration plots for the 
GARFIELD-AF risk model in ORBIT-AF and Danish AF cohort for 2 year all-cause mortality, 
non-haemorrhagic stroke/SE and major bleeding are shown in figure S2 and Figure S3. 
The predictive value of GARFIELD-AF risk models for all-cause mortality, non-haemorrhagic 
stroke/SE and major bleeding in patients enrolled in ORBIT-AF and Danish AF cohort is 
presented in Table 3. In both ORBIT-AF and Danish AF cohort, the performance of 
GARFIELD-AF risk model was good for all-cause mortality when compared to CHA2DS2-
VASc and was comparable to CHA2DS2-VASc for the prediction of non-haemorrhagic 
stroke/SE. 
 In ORBIT-AF, the performance of GARFIELD-AF risk model was comparable to HAS-
BLED score and in Danish AF cohort, the performance was better when compared to HAS-
BLED in predicting bleeding. 
Performance of the GARFIELD-AF risk models at different time points during follow-
up in the GARFIELD-AF population 
The C statistic at 30 days for all-cause mortality (C-index 0.80 (0.78-0.83)), non-
haemorrhagic stroke/SE (C-index 0.71 (0.66-0.77)) and major bleeding (C-index 0.71 (0.66-
0.77)) were slightly higher when compared to those at 1-year and 2-year follow-up (Table 4).  
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The online GARFIELD-AF calculator is available from GARFIELD-AF website 




Previous findings from GARFIELD-AF showed a higher rate of early death and an increased 
risk of stroke/SE and bleeding during the first month after newly diagnosed AF (21). However, 
as revealed in this report, risks of death, stroke/SE and major bleeding increase over time. By 
2 years, mortality risks are 3.8 fold greater than the risks of stroke/SE and of major bleeding. 
Awareness of this excess mortality risk may allow clinicians to address residual cardiovascular 
risk factors and lifestyle factors, more comprehensively (22). By incorporating risk prediction 
not only for stroke/SE but also for mortality, major bleeding, and the impact of anticoagulant 
treatment, the GARFIELD-AF predictor has the potential to enhance guideline-based treatment 
in AF. 
The GARFIELD-AF new risk model for simultaneous prediction of mortality, non-
haemorrhagic stroke/SE and major bleeding was superior to the existing risk scores for stroke 
and bleeding in AF patients over 2 years. The findings are consistent with, and they build upon, 
those reported for the GARFIELD-AF risk model at one year (4). The updated GARFIELD-
AF tool now incorporates the impact of anticoagulant treatment (VKA or NOAC) or no 
anticoagulant.  
Predictors of increased risk of all-cause mortality, non-haemorrhagic stroke/SE and major 
bleeding were older age, prior stroke, vascular disease, diabetes, CKD and history of bleeding 
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major bleeding). CHF, dementia and smoking were associated with mortality and non-
haemorrhagic stroke/SE.  Thought CKD, dementia and smoking are not the components of the 
CHA2DS2-VASc score, they had a strong influence on the risk of death and non-haemorrhagic 
stroke/SE. Similarly, CKD, vascular disease and carotid occlusive disease are not the 
components of the HAS-BLED but were associated with high risk of major bleeding. Those 
treated with a NOAC or a VKA exhibited a reduction of all-cause mortality and stroke/SE 
when compared with no OAC. NOAC treatment was associated with a lower risk of all-cause 
mortality, non-haemorrhagic stroke/SE and major bleeding when compared with VKA. These 
results were consistent with previous findings from GARFIELD-AF (23). Ethnicity was found 
to be an important predictor of the all-cause mortality but not for stroke/SE or major bleeding. 
Geographic variations were a powerful factor associated with outcomes as in the previous study 
(24). However, findings from GARFIELD-AF showed that geographic variations in outcome 
are not accounted for by differences in baseline characteristics (23).  
The GARFIELD-AF model assesses multiple variables and incorporates anticoagulant 
treatment. It performed better than CHA2DS2-VASc for all-cause mortality. The CHA2DS2-
VASc score covers the variables of congestive heart failure, hypertension, age of 75 years or 
older, diabetes mellitus Type II, previous stroke/transient ischaemic attack (TIA) or 
thromboembolism, vascular disease, age 65–74 years and female gender. However, other 
potential risk factors such as CKD, carotid occlusive disease, obesity, or smoking were not 
included in that model. R2CHADS2 or ATRIA scores to predict thromboembolic risk in 
patients with non-valvular AF include the variables ‘proteinuria’, ‘end-stage renal disease’, or 
‘estimated glomerular filtration rate (eGFR) of below 45 mL/min’. These variables are useful 
for weighing the individual thromboembolic risk in intermediate-risk patients and thus can be 
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The GARFIELD-AF integrated risk model was also superior to CHA2DS2-VASc for all-cause 
mortality and non-haemorrhagic stroke/SE or HAS-BLED for major bleeding in the very low 
to low risk patients (CHA2DS2-VASc 0 or 1 for men and 1-2 for women/ HAS-BLED 0 or 1 
for major bleeding / haemorrhagic stroke). The distribution of CHA2DS2-VASc score 
categories by GARFIELD-AF stroke score deciles showed that the 24 of very low risk patients 
according to the GARFIELD-AF stroke scores would have been categorised as CHA2DS2-
VASc ≥2 and hence, by current guidelines, indicated for anticoagulant treatment. The observed 
stroke risk remains constant as the CHA2DS2-VASc increases up to the 1st quartile of the 
population. However, using the GARFIELD-AF score, the incidence of stroke risk increased 
within this cohort. Thus, potentially, the GARFIELD-AF risk score could help clinicians apply 
the guideline recommendations. OAC use in low and very low risk patients remains 
contentious, and guidelines do not indicate a benefit for OAC treatment in such patients.  
 
Web based risk tool 
The GARFIELD-AF risk tool demonstrated good calibration and discrimination, 
outperforming CHA2DS2-VASc at predicting risk of death and non-haemorrhagic stroke/SE 
and HAS-BLED for bleeding in very low to low risk AF patients over 2 years. The online 
GARFIELD-AF calculator is available from GARFIELD-AF website 
https://af.garfieldregistry.org/garfield-af-risk-calculator and a mobile app, Calculate by Qx-
MD; https://qxmd.com/calculate/calculator_685/garfield-af-risk-calculator..  
Case Studies 
To illustrate potential applications of the GARFIELD-AF risk predictor two brief case 
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 Case 1 (figure 4a) 
Age: 62; Gender: Male; Weight: 70kg; Ethnicity: Asian; BP: 132/86 (not treated for hypertension); 
Diabetic; Renal dysfunction CrCl 45ml/min (moderate to severe); Smoker; Currently on NSAIDS for 
joint discomfort; Labile INR on warfarin and renal disease 
Risk Scores 
CHA2DS2VASc = 1  
HAS-BLED =3 points  
GARFIELD-AF risk for mortality: No OAC (4.1%), VKA (3.5%) and NOAC (2.8%) 
GARFIELD-AF risk for Ischaemic Stroke/SE:  No OAC (3.4%), VKA (2.4%) and NOAC (1.9%); 
GARFIELD-AF risk for Major bleeding including Haemorrhagic stroke: No OAC (1.2%), VKA (2.2%) 
and NOAC (1.5%) 
Treatment options  
He would probably not anticoagulated with CHA2DS2VASc 1 and HAS-BLED 3 but the GARFIELD-
AF risk scores show that the risk of death and stroke is potentially lower with anticoagulation than no 
treatment, and potentially lower bleeding risk in those treated with a NOAC when compared with VKA 
treatment. 
 
Case 2 (figure 4b) 
Age: 72; Gender: Female; Weight: 60kg; Ethnicity: Caucasian; BP: 142/86 (treated for hypertension); 
Early dementia; Renal dysfunction CrCl 50ml/min (moderate to severe); Currently on NOAC for AF 
Risk Scores 
CHA2DS2VASc = 3  
HAS-BLED =2  
GARFIELD-AF risk for mortality: No OAC (10.2%), VKA (8.5%) and NOAC (6.8%) 
GARFIELD-AF risk for Ischaemic Stroke/SE:  No OAC (4.2%), VKA (3.0%) and NOAC (2.4%) 
GARFIELD-AF risk for Major bleeding including Haemorrhagic stroke: No OAC (1.6%), VKA (2.8%) 
and NOAC (2.0%) 
Treatment options  
This patient’s CHA2DS2VASc stroke risk does not take the following risk predictors into consideration: 
she was on anticoagulation, BP142/86 with treated hypertension but not uncontrolled, age 72 
(CHA2DS2VASc uses cut points for age, not continuous risk), renal dysfunction, early dementia. 
The GARFIELD-AF risk scores show that the risks of death and stroke are potentially lower with NOAC 
treatment compared with VKA and No OAC treatment. The GARFIELD predictor indicates that the risks 
of bleeding are lower with NOACs than VKA treatment, but any anticoagulant treatment has higher 
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Easily applicable tools for a personalised refinement of the individual thromboembolic risk in 
patients with AF and a CHA2DS2-VASc score of 1 guide clinicians through the question of 
whether to anticoagulate or not. Traditional risk assessment tools rely heavily on age, sex, and 
presence of cardiovascular comorbidities, but newer tools take into account changes in risk 
factors over time and novel biomarkers to facilitate more personalized risk assessment (27). 
These tools could be embedded into electronic medical record systems for point-of-care 
decision-making. They can be developed into applications for handheld electronic devices and 
for web-based interfaces. 
Strengths and limitations of this study 
The GARFIELD-AF risk model and risk tool were derived from the global prospective 
observational registry of patients with newly diagnosed atrial fibrillation (AF), for up to 2 years 
after enrolment. The GARFIELD-AF tool simultaneously calculates risks of death, non-
haemorrhagic stroke/SE, and bleeding, based on OAC treatment selection, in a single 
calculation. The GARFIELD-AF risk score allows mortality to be assessed which give balance 
to the stroke and bleeding assessments.  It also enables treatment effects to be estimated which 
is fundamentally different to CHA2DS2-VASc and HAS BLED. 
The GARFIELD-AF risk tool was validated in the ORBIT-AF which includes patients with 
prevalent AF, whereas only new onset AF patients were enrolled in GARFIELD-AF. This 
external validation has limitations as information on carotid occlusive disease was not available 
in ORBIT-AF studies. The GARFIELD-AF risk tool was also validated in the national Danish 
AF registry and this analysis has limitations regarding the definitions of major bleeding. The 
Danish AF cohort selected ICD-10 codes for bleeding hospitalisations and GARFIELD-AF 
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Danish cohort. The GARFIELD-AF tool is applicable to patients with atrial fibrillation, who 
in the view of the managing clinician, are at risk of stroke. Overall, 33.1% of patients in 
GARFIELD-AF did not receive anticoagulation so the tool is designed to provide a context for 
clinician/patient discussions about treatment choices. GARFIELD-AF excludes patients with 
non-AF indications for anticoagulation and it excludes patients with mechanical valves and 
severe valvular heart disease. An important limitation is that only baseline data were used in 
the risk assessment. 
Clinical implications and future research directions:  
The implications of this integrated GARFIELD-AF risk tool are several. First, it allows 
clinicians to perform a single calculation for mortality, stroke and bleeding and helps resolve 
the balanced considerations of risks and benefits. Second, it provides this information for both 
anticoagulated and non-anticoagulated patients, and the impact of NOAC versus VKA therapy. 
Third, it provides important data on mortality risk, thus highlighting the need for 
comprehensive secondary prevention. Forth, it provides more accurate risk prediction in low 
risk patients, a group were CHA2DS2-VASc and HAS-BLED do not perform well. Finally, 
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 Figure Legend 
Figure 1. Comparison of the performance (C-statistic (95% CI) of the GARFIELD-AF risk 
models versus CHA2DS2-VASc (for (a) all-cause mortality and (b) non-haemorrhagic 
stroke/SE) or (c) HAS-BLED (for major bleeding/haemorrhagic stroke) at two years of 
follow-up in the whole GARFIELD-AF population and by baseline anticoagulation and risk 
category 
Very low to low risk: CHA2DS2-VASc score of 0 or 1 (men) and 1 or 2 (women); HAS-BLED 0 or 
1 for major bleeding / haemorrhagic stroke. 
Figure 2. Calibration of GARFIELD-AF risk models for all-cause mortality (a), non-
haemorrhagic stroke/SE (b), and major bleeding/haemorrhagic stroke (c) at 2 years of follow-
up in the GARFIELD-AF population 
Figure 3. Distribution of CHA2DS2-VASc score categories by GARFIELD-AF stroke score 
deciles 
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Table 1. Baseline characteristics for the whole study population and by outcome.  Events are 
not mutually exclusive. 
Variable 
All patients 
(N = 52,032) 
Outcome occurred within 2 years 
Death 
(N = 3702) 
Non-
haemorrhagic 
stroke / SE 
(N = 957) 
Major bleeding / 
haemorrhagic 
stroke 
(N = 935) 
     
Sex, n (%)     
 Male 29,042 (55.8) 2018 (54.5) 481 (50.3) 490 (52.4) 
 Female 22,989 (44.2) 1684 (45.5) 476 (49.7) 445 (47.6) 
     






76.0 (69.0; 82.0) 
Age, n (%), years     
<65 15,961 (30.2) 459 (12.4) 165 (17.2) 130 (13.9) 
65-69 8019 (15.4) 360 (9.7) 119 (12.4) 109 (11.7) 
70-74 8929 (17.2) 534 (14.4) 175 (18.3) 162 (17.3) 
≥75 19,393 (37.3) 2349 (63.5) 498 (52.0) 534 (57.1) 
     
Ethnicity, n (%)     
 Caucasian 32,005 (63.1) 2503 (61.2) 600 (64.4) 646 (71.7) 
 Hispanic/Latino 3392 (6.7) 311 (8.6) 72 (7.7) 56 (6.2) 
 Asian 14,282 (28.1) 685 (19.0) 229 (24.6) 181 (20.1) 
 Afro-Caribbean/Mixed/Other 1069 (2.1) 105 (2.9) 31 (3.3) 18 (2.0) 
      








26.5 (23.3; 30.7) 
     
Systolic blood pressure, median 
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 Permanent 6630 (12.7) 627 (16.9) 139 (14.5) 110 (11.8) 
 Persistent 7758 (14.9) 508 (13.7) 146 (15.3) 123 (13.2) 
 Paroxysmal 14,307 (27.5) 734 (19.8) 224 (23.4) 226 (24.2) 
 New onset (unclassified) 23,331 (44.8) 1833 (49.5) 448 (46.8) 476 (50.9) 
      
Care setting specialty at 
diagnosis, n (%) 
    
 Internal medicine 9370 (18.0) 852 (23.0) 222 (23.2) 197 (21.1) 
 Cardiology 34,187 (65.7) 2227 (60.2) 543 (56.7) 545 (58.3) 
 Neurology 874 (1.7) 81 (2.2) 40 (4.2) 32 (3.4) 
 Geriatrics 202 (0.4) 41 (1.1) 8 (0.8) 4 (0.4) 
 Primary care/general practice 7393 (14.2) 501 (13.5) 144 (15.0) 157 (16.8) 
      
Care setting location at 
diagnosis, n (%) 
    
 Hospital 30,341 (58.3) 2357 (63.7) 599 (62.6) 530 (56.7) 
 Office 15,581 (29.9) 924 (25.0) 247 (25.8) 249 (26.6) 
 Anticoagulation 
clinic/thrombosis centre 
339 (0.7) 24 (0.6) 8 (0.8) 6 (0.6) 
 Emergency room 5536 (10.7) 397 (10.7) 103 (10.8) 150 (16.0) 
      
Medical history, n (%)     
 Congestive heart failure 11,739 (22.6) 1466 (39.6) 272 (28.4) 216 (23.1) 
 Coronary artery disease 11,253 (21.6) 1168 (31.6) 270 (28.2) 247 (26.4) 
 Acute coronary syndromes 5536 (10.7) 653 (17.8) 153 (16.1) 155 (16.6) 
 Coronary artery bypass graft 1625 (3.2) 190 (5.2) 43 (4.5) 51 (5.6) 
 Stenting 3542 (6.9) 342 (9.3) 78 (8.2) 103 (11.1) 
 Vascular disease 12,818 (24.8) 1365 (37.2) 310 (32.6) 296 (31.9) 
 Carotid occlusive disease 1544 (3.0) 157 (4.3) 37 (3.9) 52 (5.7) 
 Pulmonary embolism/deep 
vein thrombosis 
1354 (2.6) 149 (4.1) 34 (3.6) 29 (3.1) 
 Prior stroke 3878 (7.5) 421 (11.4) 163 (17.0) 99 (10.6) 
 Prior transient ischaemic attack 2267 (4.4) 225 (6.1) 76 (8.0) 59 (6.5) 
 Prior systemic embolism 334 (0.6) 31 (0.8) 8 (0.8) 11 (1.2) 
 Prior bleeding 1316 (2.5) 204 (5.5) 43 (4.5) 54 (5.8) 
 Hypertension 39,610 (76.3) 2853 (77.3) 780 (81.7) 739 (79.4) 
 Hypercholesterolaemia 20,959 (41.6) 1425 (40.1) 423 (46.2) 410 (44.7) 
 Diabetes 11,546 (22.2) 1022 (27.6) 256 (26.8) 253 (27.1) 
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 Moderate to severe CKD 5355 (11.7) 830 (25.3) 171 (20.7) 195 (22.8) 
 Dementia 764 (1.5) 187 (5.1) 39 (4.1) 15 (1.6) 
 Hyperthyroidism 898 (1.8) 60 (1.7) 15 (1.6) 24 (2.6) 
 Hypothyroidism 3035 (6.0) 252 (7.0) 52 (5.6) 56 (6.0) 
     
Alcohol consumption, n (%)     
Abstinent 24,447 (55.5) 1965 (62.5) 462 (56.1) 420 (54.6) 
Light 14,364 (32.6) 905 (28.8) 267 (32.4) 261 (33.9) 
Moderate 4184 (9.5) 200 (6.4) 70 (8.5) 68 (8.8) 
Heavy 1026 (2.3) 72 (2.3) 24 (2.9) 20 (2.6) 
     
Smoking status, n (%)     
 Non-smoker 31,023 (65.4) 2059 (61.1) 576 (64.6) 525 (61.9) 
 Ex-smoker 11,203 (23.6) 978 (29.0) 206 (23.1) 241 (28.4) 
 Current smoker 5198 (11.0) 335 (9.9) 109 (12.2) 82 (9.7) 
      
Treatment at baseline, n (%)     
 NOAC ± AP 14,123 (27.5) 835 (22.9) 204 (21.7) 231 (25.3) 
 VKA ± AP 20,183 (39.3) 1463 (40.2) 351 (37.3) 468 (51.3) 
 AP only 10,761 (21.0) 871 (23.9) 269 (28.6) 129 (14.3) 
 None 6240 (12.2) 473 (13.0) 117 (12.4) 85 (9.3) 
      
CHA2DS2-VASc score, median 
(Q1; Q3) 
3.0 (2.0; 4.0) 4.0 (3.0; 5.0) 4.0 (3.0; 5.0) 4.0 (3.0; 5.0) 
     
HAS-BLED score, median (Q1; 
Q3)1 
1.0 (1.0; 2.0) 2.0 (1.0; 2.0) 2.0 (1.0; 2.0) 2.0 (1.0; 2.0) 
     
     
1The risk factor ‘Labile INRs’ is not included in the HAS-BLED score as it is not collected at 
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Table 2a. Wald Chi-square, p-values and hazard ratios for components of the GARFIELD 
all-cause mortality model 







Age1 956 <.0001  
up to 65 years   1.17 (1.11-1.23) 
65 years or older   1.38 (1.35-1.42) 
Congestive heart failure 403 <.0001 2.00 (1.87-2.14) 
Ethnicity (ref.: Caucasian) 197 <.0001  
Hispanic/Latino   1.17 (1.04-1.32) 
Asian   0.54 (0.49-0.60) 
Afro-Caribbean/Mixed/Other   1.46 (1.20-1.77) 
Diastolic blood pressure (up to 80 mmHg)1 100 <.0001 0.91 (0.89-0.93) 
Weight (up to 75 kg)1 98 <.0001 0.90 (0.88-0.92) 
Pulse (up to 120 bpm)1 96 <.0001 1.04 (1.03-1.05) 
Moderate to severe CKD 89 <.0001 1.46 (1.35-1.58) 
Treatment (ref.: No OAC) 89 <.0001  
NOAC   0.66 (0.61-0.72) 
VKA   0.83 (0.77-0.90) 
Vascular disease 74 <.0001 1.36 (1.27-1.46) 
Female sex 71 <.0001 0.74 (0.69-0.79) 
Diabetes 55 <.0001 1.32 (1.23-1.43) 
Dementia 40 <.0001 1.63 (1.40-1.90) 
Current smoker 36 <.0001 1.41 (1.26-1.58) 
History of bleeding 28 <.0001 1.47 (1.27-1.70) 
Prior stroke 26 <.0001 1.31 (1.18-1.45) 
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Table 2b. Wald Chi-square, p-values and hazard ratios for components of the GARFIELD 
non-haemorrhagic stroke/SE and major bleeding models 
Model Chi-square P-value Hazard Ratio (95% CI) 
Non-haemorrhagic stroke/SE 
model 
   
Age1 132 <.0001 1.22 (1.18-1.26) 
Prior stroke 84 <.0001 2.23 (1.88-2.64) 
Treatment (ref.: No OAC) 49 <.0001  
NOAC   0.56 (0.48-0.67) 
VKA   0.70 (0.61-0.81) 
Current smoker 22 <.0001 1.61 (1.32-1.97) 
Diastolic blood pressure (80 
mmHg or more)1 
20 <.0001 1.08 (1.05-1.12) 
Moderate to severe CKD 17 <.0001 1.42 (1.20-1.67) 
Congestive heart failure 10 0.0015 1.26 (1.09-1.46) 
Dementia 9 0.0022 1.67 (1.20-2.32) 
Diabetes 8 0.0041 1.24 (1.07-1.43) 
Vascular disease 8 0.0057 1.22 (1.06-1.40) 
History of bleeding 3 0.0555 1.35 (0.99-1.83) 
    
Major bleeding    
Age1 156 <.0001 1.24 (1.20-1.29) 
Treatment (ref.: No OAC) 56 <.0001  
NOAC   1.27 (1.05-1.55) 
VKA   1.84 (1.55-2.18) 
Moderate to severe CKD 36 <.0001 1.65 (1.40-1.94) 
History of bleeding 31 <.0001 2.19 (1.66-2.88) 
Pulse (bpm)1 12 0.0005 1.02 (1.01-1.03) 
AP treatment (ref.: no AP 
treatment) 
9 0.0021 1.27 (1.09-1.47) 
Diabetes 6 0.0176 1.19 (1.03-1.38) 
Vascular disease 5 0.0250 1.18 (1.02-1.37) 
Carotid occlusive disease 5 0.0281 1.37 (1.03-1.82) 
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Table 3. Evaluation of the performance (C-statistic (95% CI)) of the GARFIELD-AF risk 
models versus CHA2DS2-VASc (for all-cause mortality and non-haemorrhagic stroke/SE) or 
HAS-BLED (for major bleeding/haemorrhagic stroke) at two years of follow-up in the ORBIT-
AF study population and Danish AF cohort. 










































ORBIT-AF: History of bleeding and carotid occlusive disease were not available; Danish AF Cohort: 
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Table 4. Evaluation of the performance (C-statistic (95% CI)) of the GARFIELD risk models at 
different time points during follow-up in the GARFIELD-AF population 
Model 
Time of follow-up 
30 days 1 year 2 years 
All-cause mortality 0.80 (0.78-0.83) 0.76 (0.75-0.77) 0.75 (0.74-0.76) 
Non-haemorrhagic stroke/SE 0.71 (0.66-0.77) 0.70 (0.68-0.72) 0.68 (0.67-0.70) 
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